A Dissertation on

ECG AND ECHOCARDIOGAPHIC

FINDINGS IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE

Dissertation submitted to

THE TAMILNADU Dr.M.G.R.MEDICAL UNIVERSITY

CHENNAI - 32.

with partial fulfillment of the regulations

for the award of the degree of

M.D. GENERAL MEDICINE

BRANCH - I

INSTITUTE OF INTERNAL MEDICINE

MADRAS MEDICAL COLLEGE,
CHENNAI - 600 003.

MARCH 2007
 CERTIFICATE

This is to certify that this dissertation in "ECG AND

ECHOCARDIOGRAPHIC FINDINGS IN CHRONIC OBSTRUCTIVE

PULMONARY DISEASE" was a work done by Dr.B.ANTONY

BENEDICT BABU under my guidance during the academic year 2004-2007.

This has been submitted in partial fulfillment of the award of M.D.Degree in

General Medicine (Branch-I) by the Tamil Nadu Dr.M.G.R. Medical

University, Chennai - 600 032.

Prof.Dr.P.Thirumalaikozhundhu Prof.Dr.D.B.Selvaraj ,M.D.,

Subramanian, M.D., Add. Prof. of Internal Medicine
Director, Professor & Head, Chief, Medical Unit - VII
Institute of Internal Medicine, Institute of Internal Medicine
Madras Medical College & Madras Medical College & Hospital
Govt. General Hospital, Chennai - 600 003.
Chennai - 600 003.

THE DEAN
Madras Medical College & Hospital
Chennai - 600 003.
 DECLARATION

I solemnly declare that this dissertation entitled "ECG AND

ECHOCARDIOGAPHIC FINDINGS IN CHRONIC OBSTRUCTIVE

PULMONARY DISEASE " was done by me at Madras Medical College and

Government General Hospital during the academic year 2004 - 2007 under the

guidance and supervision of Prof.Dr.D.B.SELVARAJ, M.D. This dissertation

is submitted to the Tamil Nadu Dr.M.G.R. Medical University, towards the

partial fulfillment of requirement for the award of M.D. Degree in General

Medicine (Branch - I).

Place:
Dr.B.ANTONY BENEDICT BABU
Date:
 SPECIAL ACKNOWLEDGEMENT

I gratefully acknowledge and sincerely thank Prof.Kalavathi

Ponniraivan, B.Sc., M.D., Dean, Madras Medical College and Government

General Hospital, Chennai, for granting me permission to utilize the resources

of the institution for my study.

 ACKNOWLEDGEMENTS

I sincerely thank Dr. P. Thirumalaikolundusubramanian M.D.,

Director and Professor, Institute of Internal Medicine, Madras Medical College,

Chennai for allowing me to utilize the hospital facilities for my dissertation

studies.

I sincerely thank Dr. D. B. Selvaraj M.D., Additional Professor of

Internal Medicine, Institute of Internal Medicine, Madras Medical College,

Chennai and my unit chief for his constant support and guidance in doing my

dissertation studies.

My sincere thanks to Dr. K. Chandra M.D., Former Additional

Professor of Internal Medicine, Madras Medical College and my former chief

for guiding me in my dissertation studies.

My sincere thanks to Dr. Basheer Ahmed M.D., Assistant Professor,

Allergy Asthma Clinic, Madras Medical College, Chennai for helping me in

my studies.

I sincerely thank Dr. Kani Sheikh Mohammed M.D., Dr. Sivakumar

M.D., Assistant Professors, Institute of Internal Medicine, Chennai for guiding

me in my studies.

My sincere thanks to Dr. S. Shanmugasundaram M.D., D.M.,

Additional Professor of Cardiology (Retd.), for helping me in my studies.

 CONTENTS

Sl.No. Title Page No.

1. Introduction 1

2. Review of literature 2

3. Aims and objectives 17

4. Materials and methods 18

5. Observation 30

6. Discussion 40

7. Conclusion 52

8. Summary 53

9. Bibliography

10. List of Tables

11. List of Figures

12 Master chart
 1

INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) which encompasses

both chronic bronchitis and emphysema is one of the commonest respiratory

condition of adults in the developing world.

In the western world, COPD is probably the fourth commonest cause of

death in middle aged to elderly men. According to estimates, COPD would

become the third biggest cause of death in the world by 2020.

Going by the available Indian data for 1996, there were 12.3 million

cases of COPD in our country. COPD poses an enormous burden to our

society, both in terms of direct cost to health care services and indirect cost to

society in terms of loss of production.

Despite the high prevalence and enormous cost to health care and

society, COPD has received little attention in respect to other respiratory

conditions like Asthma and Lung Cancer.

This is likely to be because COPD is thought of as a self inflicted

disease with few effective treatments and mainly affects a more elderly which

has less vocal population, which is not true.

 2

REVIEW OF LITERATURE

HISTORICAL PERSPECTIVE

The beginning of modern chest medicine can be traced to the classic

volume by Laennec, “A treatise on diseases of the chest” which appeared in

1821 laid the corner stone of modern chest medicine.

In his treatise, Laennec, devoted one chapter to “Pulmonary Catarrh or

Bronchitis” and emphysema. The chapter on bronchitis distinguishes between

acute and chronic form and sub divides chronic bronchitis into two types – the

humid (Copious Expectoration) and dry (Scarcely any Expectoration). He

identified “Dilatation of air cells” as the essential feature of emphysema.

Recognition of chronic bronchitis as a potentially grave illness rather

than as a trivial but not disabling disease had to wait the “London Fog” of

1953, which was brought about by bad weather and air pollutants, carried with

it a surge in morbidity and mortality due to chronic lung disease.

After World War II, clinical investigations of pulmonary disease were

provided with a new diagnostic armamentarium; Pulmonary Function tests

were extended beyond simple spirometry and innovative techniques were

developed for assessing the distribution of gases within the lungs which greatly

improved our understanding of COPD.

 3

DEFINITION

The Global Initiative on Obstructive Lung Disease (GOLD) has

proposed a definition of COPD that is based on evidence of air flow

obstruction. Accordingly it is defined as a “disease state characterized by air

flow limitation that is not fully reversible. The air flow limitation is usually

both progressive and associated with an abnormal inflammatory response of the

lungs to noxious particles or gases”.

1. Chronic Bronchitis

It is defined as persistence of cough and excessive mucous secretion on

most days over a three month period for at least two successive years.

2. Emphysema

It is defined as abnormal permanent enlargement of the gas exchanging

unit of lungs in association with destruction of alveolar walls and without

obvious fibrosis.

Burden of COPD

Epidemiology

Most of the information available on COPD prevalence, morbidity and

mortality comes from developed countries. Even in these countries, accurate

epidemiological data on COPD are difficult and expensive to collect.

Prevalence and morbidity data greatly underestimate the total burden of

COPD because the disease is usually not diagnosed until it is clinically
 4

apparent and moderately advanced. The imprecise and variable definitions have
made it hard to quantify the morbidity and mortality of this disease in
developed and developing countries.

Prevalence

In the “Global burden of disease” study conducted by World Health

Organization (WHO) the world wide prevalence of COPD in 2002 was
estimated to be 11.6 / 1000 in men and 8.77 / 1000 in women. The prevalence
is highest in countries where cigarette smoking has been, or still is very
common.

Globally, the study showed COPD results in 2.75 million deaths overall
representing 4.8 % of all deaths.

Now COPD is the fourth leading cause of death worldwide and by the
year 2020 it will be the third leading cause of death and fifth leading cause of
DALY’s lost worldwide (Disability Adjusted Life Years).

Pathogenesis

COPD is characterized by chronic inflammation through out the

airways, parenchyma and pulmonary vasculature. Macrophages , T
lymphocytes (Predominantly CD 8 + ) and neutrophils are increased in various
parts of the lung. Activated inflammatory cells release a variety of mediators
including leukotriene B4, interleukin 8, tumor necrosis factor (TNF) and others
capable of damaging lung structures and / or sustaining neutrophilic
inflammation.
 5

In addition to inflammation, two other processes thought to be important in

the pathogenesis of COPD are:

(i) imbalance of proteinases and anti proteinases in the lung

(ii) oxidative stress

Pathology

Pathological changes characteristic of COPD are found in the central

airways, peripheral airways, lung parenchyma and pulmonary vasculature.

Central airways (> 2-4 mm in internal diameter)

Enlarged mucus secreting glands

Increase in the number of goblet cells

Peripheral airways (< 2 mm in internal diameter)

Structural remodeling of the airway wall, with increasing collagen

content and scar tissue formation that narrows the lumen and produces fixed

airway obstruction.

Lung parenchyma

Centri lobular emphysema is predominantly seen in these patients

because it is the most frequent type of emphysema seen in smokers. Recent

studies indicate increased collagen per unit volume of air space wall in

emphysematous lung from smokers.

 6

Pulmonary vasculature

There will be thickening of the intima initially followed by smooth

muscle hyperplasia as the disease progresses.

Pathophysiology

Pathological changes in the lungs lead to corresponding physiological

changes characteristic of the disease which occur in the following order:

Mucus hypersecretion

Ciliary dysfunction

Airflow limitation

Pulmonary hyperinflation

Gas exchange abnormalities

Pulmonary hypertension

Cor pulmonale
 7

Clinical hallmarks

Table - 1

Predominant bronchitis Predominanat

emphysema

General Mesomorphic; overweight, Thin, often emaciated,

appearance dusky with suffused pursed lip breathing,
conjunctivae, warm anxious, normal or cool
extremities extremities

Age, years 40 to 55 years 50 to 75 years

Onset Cough Dyspnea

Cyanosis Marked Slight to none

Cough More evident than dyspnea

Sputum Copious Scanty

Upper respiratory Common Occasional

infections

Breath sounds Moderately diminished Markedly diminished

Corpulmonale Common Only during bouts of

and right sided respiratory infection and
heart failure terminal

Other names Blue bloater Pink puffer

Pink puffer

Complains of severe dyspnea but has a relatively good blood oxygen

level and does not have hypercapnia. Such patients tend to be thin and does not

have corpulmonale or right sided heart failure.

 8

Blue bloater

He has peripheral edema caused by right heart failure and has more

severe hypoxemia and hypercapnia and less dyspnea.

Cardio vascular manifestations

COPD is associated with several complications, the most serious of

which are Pulmonary arterial hypertension, right ventricular hypertrophy

(Corpulmonary) and right ventricular failure.

Chronic corpulmonary is defined as “ hypertrophy of the right ventricle

resulting from the disease affecting the function and / or structure of the lung,

except when these pulmonary alterations are the result of diseases that

primarily affect the left side of the heart or congenital heart disease”.

Pathophysiology of pulmonary hypertension

Pulmonary hypertension in COPD is due to multiple factors.:

(i) Pulmonary vasoconstriction caused by alveolar hypoxia, academia

and hypercarbia

(ii) Compression of pulmonary vessels by the high lung volume

(iii) Loss of small vessels in the vascular bed in regions of emphysema

and lung destruction

(iv) Increased cardiac output and blood viscoscity from polycythemia

secondary to hypoxia
 9

Of these, hypoxia is the most important factor and is associated with

pathological changes that occur characteristically in the peripheral pulmonary
arterial bed.

Intimal thickening appears to be a early event that occurs in association

with progressive airflow limitation. The structural rather than hypoxic
vasoconstriction is required for the development of sustained pulmonary
hypertension in patients with COPD.

With mild to moderate grades of COPD, (FEV1 40% to 80% of

predicted), pulmonary artery pressure (Ppa) is usually normal at rest, but
increases with moderate exercise or exposure to cold. In the presence of severe
COPD (FEV1 < 40% of predicted), hypertension is usually present at rest
(Mean Ppa > 20 mm Hg) and pulmonary arterial pressure undergoes a
disproportionate increase with mild exercise.

Ppa can increase acutely during episodes of hypoxia that occur during
sleep and it has been suggested that recurrent nocturnal pulmonary
hypertension can eventually lead to “fixed” hypertension as a result of
structural changes in the arterial wall.

Pulmonary hypertension in COPD progresses over time and its severity

correlates with the degree of airflow obstruction and impairment of pulmonary
gas exchange.

Weitzenblum et al studied the evolution of Ppa in a group of 93

patients with COPD for 5 years. They found that Ppa increased at an average
rate of 0.08 kPa (0.6mm Hg) per year. The rate of increase of Ppa was slightly
higher in patients who did not have pulmonary hypertension at the beginning of
the study compared with those who already had pulmonary hypertension.
 10

An intriguing question is when pulmonary hypertension commences in

the natural history of COPD. In a recent study, Kessler et al assessed the
evolution of pulmonary hemodynamics in a group of 131 patients with
moderate COPD who did not have pulmonary hypertension at rest, although
58% developed pulmonary hypertension during exercise.

The results of the study indicates that in COPD, changes in pulmonary

circulation may start several years before pulmonary hypertension is apparent
at rest and that exercise testing might be useful in showing abnormalities of the
pulmonary circulation.

Although left ventricular function is normal in most patients who have

COPD, it may deteriorate when corpulmonale and right ventricular failure
develop because of right ventricular dilatation, septal shift and left ventricular
compliance.

Chronic corpulmonale is associated with a high incidence of cardiac

arrhythmias, particulary supra ventricular arrhythmias.

ELECTRO CARDIOGRAPHIC MANIFESTATIONS

Chronic obstructive airways disease influence the electrical events of the

heart in the following basic respects:

1. the voluminous lungs have an insulating effect and thereby diminish the
transmission of electrical potential to the registering electrodes

2. the heart descends to a lower position within the thorax due to a

lowering of the diaphragm. This will alter the position of the heart
relative to conventional precordial electrode postions.
 11

3. the right ventricle and right atrium become compromised due to a

reduction of the pulmonary vascular bed. This will result in right

ventricular hypertrophy as well as right atrial enlargement.

Decreased magnitude of the electrocardiographic deflexions

The voluminous lungs impair electrical transmission. The QRS and T

deflexions are therefore markedly diminished in magnitude.

Lead I sign

In patients with COPD the frontal plane P, QRS and T wave axes are not

infrequently all directed at around + 90 degree which are either precisely or

almost perpendicular to the standard lead I axis. As a result of this Lead I

reflects absent or very low amplitude P, QRS and T wave complexes giving the

appearance of minimally disturbed base line. This ECG phenomenon is known

as the Lead I sign.

Right atrial enlargement

The frontal plane P wave axis is directed to the right of +60 degree. It is

commonly and in a way characteristically directed to + 90 degree

P pulmonale

It is reflected by P waves which are tall and peaked in standard leads II,

III aVF, and is the expression of right atrial enlargement.

 12

The combination of right axis deviation and tall peaked P waves is

called P pulmonale. A comparison of interstitial pulmonary fibrosis and COPD

showed that a deviation of the frontal plane P wave axis to the right of +70

degree only occurs with COPD.

Abnormalities of the QRS complex

Right QRS axis deviation

The frontal plane QRS axis is deviated to the right and commonly

directed to +90 degree. When it is deviated further, the frontal plane leads will

usually reflect an S1Q3R3 pattern. In very severe cases it may be directed to

the “northwest” region.

Left QRS axis deviation

This occurs in about 10% of cases. The mechanism is still speculative.

S1, SII, SIII syndrome

Prominent terminal S waves may appear in standard leads I and II or in

I, II and III giving rise to the SI, S II, S III syndrome. This indirectly reflects

posterior displacement of the apex.

Posterior displacement of the mean QRS axis

The mean QRS axis may also be displaced somewhat posteriorly so that

it tends to be more obliquely oriented to the horizontal plane.

 13

Abnormalities of the precordial QRS form

There is diminution of QRS magnitude in all the leads. It is not

uncommon for all the precordial leads to reflect rS complexes. In very severe

cases the R : S ratio is usually less than 1 in leads V4 to V6, and R wave

amplitude in lead V6 may be less than 5 mm. The transition zone is frequently

displaced to V6 or even further to the left.

Right bundle branch block

There may occasionally be transient complete or incomplete RBBB with

an exacerbation of the emphysema and increase in oxygen desaturation.

Right ventricle hypertrophy is mainly reflected by:

a. right axis deviation

b. prominent terminal S waves in the left precordial leads

The single most characteristic ECG feature of diagnosis in COPD is said

to be P wave axis of +70 to +90 degrees.

Abnormalities of T waves

Frontal T wave axis

It is usually similar in direction to that of QRS axis. The T wave is

diminished in amplitude in all leads. The T wave may be inverted in the right

precordial leads especially when pulmonary hypertension is marked.

 14

Exacerbation of the disease with an increase in oxygen desaturation may

be associated with elevation of ST segment in leads II, III and AVF. This
manifestation is reversible.

ECHOCARDIOGRAPHY

Echocardiography is nearly twice as sensitive as clinical examination in

detecting corpulmonale. However it may be suboptimal in persons with hyper
inflation because of poor transmission of sound waves by the increased
retrosternal air space.

Systolic pulmonary artery pressure can be estimated with pulsed

Doppler by determining the blood flow velocity in the main pulmonary artery
or in the regurgitant jet from the tricuspid valve. The tricuspid valve regurgitant
jet can be used to determine the right ventricular – atrial gradient using the
modified Bernoulli’s equation

P = 4 V2

Where P = peak pressure difference between the right ventricle (RV)

and the right atrium (RA)

V = peak velocity of tricuspid regurgitant jet

This pressure is then added to the mean right atrial pressure to obtain the
systolic Ppa.

Sensitivity, specificity and positive and negative predictive values of

systolic pulmonary artery pressure estimation for diagnosis of pulmonary
hypertension were 85, 55, 52 and 87% respectively.
 15

M Mode, 2D – Echo and Color Doppler features of patients with PAH

Table 2

Variables Right heart Left heart

M - mode

Diminished or absent atrial wave of the pulmonary valve

2D
Echo
RV hypertrophy, RV Dilatation Reduced LV end diastolic
volume
RV abnormal systolic function Reduced LV end systolic
volume
RV pressure overload pattern of LV ejection fraction within
IVS normal limits
Right atrial dilatation Increased IVS thickness
Dilated pulmonary artery IVS / posterior wall thickness
ratio more than 1
Inter atrial septum bows right to
left

Color
Doppler
Tricuspid regurgitation
Pulmonary insufficiency
Elevated pulmonary artery systolic pressure E/A ratio < 1
RV outflow tract acceleration time < 0.1 seconds
 16

E/A Ratio

Ratio between early peak transmitral flow velocity and late peak systolic

velocity

RV – right ventricle

LV – left ventricle

IVS – inter ventricular septum

 17

AIMS AND OBJECTIVES

To study the electrocardiographic and echocardiographic changes in

chronic obstructive pulmonary disease.

 18

MATERIALS AND METHODS

SETTING

The study was conducted in Government General Hospital, Chennai.

DESIGN OF STUDY

It was an observational type of study. Interview technique was used to

collect information on a predesigned proforma.

PERIOD OF STUDY

It was conducted in a time period from June 2005 to June 2006.

SAMPLE SIZE

Fifty cases of COPD.

SELECTION OF STUDY SUBJECTS

COPD patients above 30 years of age, attending the outpatient clinic in

the admission day of my unit and who were admitted in my ward in

Government General Hospital, Chennai were selected for this study.

INCLUSION CRITERIA

All COPD patients above 30 years of age, diagnosed clinically

and satisfying the spirometric criteria were included in the study.

 19

A diagnosis of COPD should be considered in any patient who

has symptoms of

i. Chronic cough

- Present intermittently or everyday

- Often present throughout the day

- Seldom only nocturnal

ii. Chronic sputum production

- Any pattern of Chronic sputum production may indicate COPD

iii. Dyspnea that is

- Progressive (worsens over time)

- Persistent (present everyday)

- Worse on exercise

- Worsens during respiratory infections

iv. History of exposure to risk factors

 20

RISK FACTORS

Table 3

Environmental Host -Related

Indoor air pollution from biomass Airway hyper responsiveness

fuel use in setting of inadequate
ventilation

Occupational dusts and chemicals Severe hereditary alpha1antitrypsin

deficiency.

History of severe childhood Low birth weight

respiratory infections

Outdoor air pollution Maternal cigarette smoking during

gestation

Low socio economic status

Intra venous drug use (Methyl

Phenidate, Methadone, Talc
granulomatosis)

Of these, cigarette smoking is overwhelmingly the most important risk

factor in the development of COPD.

Spirometric criteria

The diagnosis is confirmed by spirometry. The presence of a post

bronchodilator FEV 1 < 80% of the predicted value in combination with an

FEV 1 / FVC < 70% confirms the presence of air flow limitation that is not

fully reversible.
 21

Exclusion criteria

Patients with other respiratory diseases like:

Asthma

Tuberculosis

Bronchiectasis

Lung malignancy were excluded from the study.

Patients with:

Valvular heart diseases

Coronary heart diseases

Systemic hypertension

Cardio myopathies

AIDS were excluded.

All patients were subjected to:

- Routine blood investigations

- Urine analysis

- Sputum analysis for AFB stain, gram stain, culture and sensitivity
was done.

- Mantoux test was done

 22

- ELISA for HIV

- Arterial blood gas analysis

- Chest X-ray PA views and lateral views were taken for all
patients

- Electrocardiograph was taken

- All patients were subjected to both 2 D and Doppler

Echocardiogram and pulmonary artery pressure measured.

- Pulmonary function test was done using spirometry

SPIROMETRY

Several tests are used to study various aspects of pulmonary functions.

Amongst these spirometry is the most basic and useful method for evaluating

pulmonary function.

Spirometry is a simple expression of a complex process, just like blood

pressure. It measures air flow from fully inflated lungs over time in litres. Thus

the forced vital capacity (FVC) is the amount of air exhaled from fully inflated

lungs and FEV 1 measures the air flow during the first part of vital capacity

manoeuvre.

Selecting a Spirometer

The American Thoracic Society (ATS) recommends that the equipment

should be such that:

 23

- it can be calibrated with a three litre syringe

- it should record atleast FVC and FEV1

- it should record a flow volume curve or a flow volume loop or both (if

possible)

Contra indications for performing Spirometry

It is recommended that patients should not be tested within one month of

myocardial infarction.

Patients with any of the conditions listed below are unlikely to achieve

optimal or reproducible results.

- Chest or abdominal pain of any cause

- Oral or facial pain exacerbated by a mouth piece

- Stress incontinence

- Dementia or confused state

Performing Spirometry

According to the current ATS statement, spirometry may be performed

either in the sitting or standing position. The sitting position is considered safe

in order to prevent falling due to syncope. However, in obese subjects, the

standing position may be preferred.

- Smoking within one hour of testing

- Consuming alcohol within four hours of testing

- Performing vigorous exercise within thirty minutes of testing

 24

- Wearing clothing that substantially restricts full chest and abdominal

expansion

- Eating a large meal within two hours of testing

If it is performed to diagnose airway disorder, avoid:

- Short acting bronchodilators within previous six hours

- Long acting bronchodilators within previous twelve hours

- Slow release theophyllines within the previous twenty four hours

Spirometric manoeuvre

The procedure must be instructed and demonstrated to the patient. The

patient then performs spirometry in the following steps:

Expiratory manoeuvre

1. Take a full deep breath away from the spirometer

2. Hold the mouth piece between the lips to create a good seal

3. Expire as fast and as hard as possible for as long as possible until no

breath is left

Expiratory and inspiratory manoeuvre

1. Hold the mouth piece between the lips to create a good seal

2. Breathe in and out for two to three tidal breaths

3. Expire as fast and as hard as possible for as long as possible until no

breath is left

4. Inspire rapidly to maximum capacity

 25

Spirometry should be recorded fifteen to thirty minutes after

administration of a short acting beta-agonist eg. 200 to 400 microgram of

salbutamol to check for bronchodilator reversibility.

Acceptable tests

- The effort should be maximal, smooth and cough free

- Exhalation time should be atleast six seconds

- End of test is indicated by a two second volume plateau

- Reproducibility as indicated by FVC should be within 5% or 100 ml

between the highest and next best among three acceptable tests

- If three reproducible tests are not available, upto 8 manoeuvres should

be attempted

- The best values of three acceptable tests are used for interpretation

- If after 8 manoeuvres, 3 reproducible tests are not available, then the test

with highest values may be used.

Reversibility testing

Broncho dilator reversibility

Spirometry is recorded fifteen to thirty minutes after administration of

short acting beta agonist eg. 200 to 400 mcg of salbutamol is used.
 26

Calculation of % improvement

FEV1 (post broncho dilator) – FEV1 (base line)

x 100
FEV1 (base line)

Good bronchodilator reversibility is indicated by improvement in FEV1

by 200 ml and > 12%.

Spirometry in COPD

Gold standard for confirmation of COPD

- Decreased FEV1 with concomitant reduction in FEV1 / FVC ratio with

a poor or absent broncho dilator reversibility and normal or reduced

FVC

- FEV1 / FVC % < 70 is used to diagnose COPD

For assessment of Severity of COPD by FEV1%

Severity of COPD (GOLD classification)

Table 4

0 At risk Spirometry normal but symptoms evident

I Mild FEV1 / FVC % < 70 FEV1 > 80% predicted
II Moderate FEV1 / FVC % < 70 FEV1 50 to 80% predicted
III Severe FEV1 / FVC % < 70 FEV1 30 to 50% predicted
IV Very FEV1 / FVC % < 70 FEV1 < 30% predicted (or)
severe FEV1 < 50% predicted with
chronic respiratory failure
 27

PROFORMA

Name: Age: Sex:

Height (metres): Weight (Kgs):

Occupation: Income:

Presenting complaints

Cough with expectoration

Dyspnea

Wheeze

Cyanosis

Puffiness of face

Reduced urine output

Swelling of legs

Chest pain

Palpitation

Past history

Tuberculosis

Systemic hypertension

Diabetes mellitus

Asthma

Ischemic heart disease

Previous hospitalization for similar complaints

 28

Personal history

Diet veg or Non-Veg

Smoking–cigarettes or beedis - number of packs per day and duration of

smoking

Chewing pan

Alcohol intake

Occupational history

Investigation

Blood hemogram

Blood sugar

Blood urea

Serum creatinine

Lipid profile

Sputum

Gram stain

AFB stain

Culture and sensitivity

Mantoux test

ELISA for HIV

Urine

Albumin

Sugar

Deposits
 29

Chest X-ray

PA view

Lateral view

ECG in all leads

Arterial blood gas (ABG) analysis

Echo cardiography

Pulmonary function test

Percentage predicted

FEV1

FVC

FEV1 / FVC %

PEFR
 30

OBSERVATION

AGE – DISTRIBUTION

Table 5

S. Age Predominant Predominant Total percentage

No. (years) bronchitis emphysema

1. 30- 39 2 - 2 4

2. 40 - 49 10 2 12 24

3. 50 – 59 16 6 22 44

4. 60 & above 7 7 14 28

Lower age limit of 30 years was selected because this was the most

frequently available cut off age in the reported studies. More over COPD is rare

below this age.

In my study, it is seen predominantly in persons over 40 years of age

 31

SEX DISTRIBUTION

Table 6

S. No Sex Predominant Predominant Total Percentage

bronchitis emphysema

1. Male 23 11 34 68

2. Female 12 4 16 32

The male female ratio is 2.12:1.

 32

SMOKING PATTERN

Table 7

S. Pack years Predominant Predominant Total Percentage

No bronchitis emphysema

1. > 30 12 6 18 36

2. 20 – 30 8 3 11 22

3. < 20 3 1 4 8

4. Non smoker 12 5 17 34

Pack year

It is calculated by multiplying the number of packs of cigarettes smoked

per day by the number of years the person has smoked.

Commonly seen in persons with a smoking pattern of more than 20 pack

years.

33 of the 34 non smokers in this study were females.

 33

PULMONARY FUNCTION TEST

SPIROMETRY

Table 8

S. No FEV1 / Predominant Predominant Total Percentage

FVC % bronchitis emphysema

1. 30 – 40 3 1 4 8

2. 41 – 50 20 4 24 48

3. 51 - 60 11 8 19 38

4. 61 – 70 1 2 3 6

Table 9

S. Post Predominant Predominant Total Percentage

No bronchodilator bronchitis emphysema
FEV1%
1. Mild (> 80%) 1 2 3 6
Moderate
2. 16 8 24 48
(50 – 80 %)
Severe
3. 14 3 17 34
(30 – 50 %)
Very severe
(< 30) or
4. (< 50% with 4 2 6 12
respiratory
failure)
 34

FVC (Forced vital capacity)

Maximal volume of air that can be exhaled during a forced manoeuvre

FEV1

Volume of air expired in the first second of maximal expiration after a

maximal inspiration.

This is a measure of how quickly the lungs can be emptied.

FEV1 / FVC %

FEV1 expressed as a percentage of FVC gives a clinically useful index

of air flow limitation when it is less than 70 %.

In this study most of the cases had FEV1 / FVC % in the range between

40 to 60% and most of them had moderate to severe COPD.

 35

CHEST X-RAY FINDINGS

Table 10

S. CXR findings Predominant Predominant Total Percentage

No bronchitis emphysema

Emphysematous
1. 4 12 16 32
changes

Increased broncho
2. 24 3 27 54
vascular markings

3. Cardiomegaly 4 2 6 12

Evidence of pulmonary
4.
hypertension 6 - 6 12

More than half of them had increased broncho vascular markings.

Evidence of pulmonary hypertension was found in six patients.

 36

ARTERIAL BLOOD GAS ANALYSIS

Measurement of PaO2

Table 11

S.No PaO2 Predominant Predominant Total Percentage

(mmhg) bronchitis emphysema

1. 50 - 60 9 4 13 26

2. 40 – 49 6 1 7 14

3. < 40 2 - 2 4

Measurement of PCO2

Table 12

S. No PCO2 Predominant Predominant Total Percentage

(mmhg) bronchitis emphysema

1. 41 - 50 5 3 8 16

2. 51 – 60 3 - 3 6

3. > 60 2 - 2 4

22 patients had evidence of hypoxemia and thirteen patients had

hypercapnia.
 37

ELECTRO CARDIOGRAPHIC FINDINGS

Table 13

S. ECG changes Predominant Predominant Total Percentage

No bronchitis emphysema
1. P Pulmonale 6 2 8 16
2. Right axis deviation 10 3 13 26
3. Left axis deviation 1 - 1 2
4. RBBB - 2 2 4
5. Low voltage QRS 1 4 5 10
6. Lead I sign 2 - 2 4
7. R/S ratio in V6 < 1 8 4 12 24
8. R/S ratio in V1 > 1 5 1 6 12
9 ST depression in L II, 4 3 7 14
III, AVF
10. T Wave Inversion in 4 2 6 12
V1 – V3
11. S I, S II, S III 1 - 1 2
12. Ventricular ectopics 1 1 2 4
13. Multifocal atrial 1 - 1 2
tachycardia

In my study of 50 patients with COPD, the following

electrocardiographic findings were observed:

Right axis deviation - 13 cases

R/S ratio < 1 in V6 - 12 cases

“P” pulmonale - 8 cases

ST depression in II, III, aVF - 7 cases

 38

T wave inversion in V1 – V3 - 6 cases

Low voltage QRS - 5 cases

Right bundle branch block - 2 cases

Lead I sign - 2 cases

Ventricular ectopics - 2 cases

SI, SII, SIII pattern - 1 case

Multifocal atrial tachycardia - 1 case

ECG evidence of right ventricular hypertrophy was found in 28 cases.

 39

MEASUREMENT OF PULMONARY ARTERY PRESSURE BY ECHO-

DOPPLER

Table 14

Systolic pulmonary
Predominant Predominant
S. No artery pressure Total Percentage
bronchitis emphysema
(mmhg)

1. 31 – 40 8 2 10 20

2. 41 – 50 6 1 7 14

3. 51 – 60 2 - 2 4

4. 61 – 70 1 - 1 2

5. 71 – 80 1 - 1 2

21 patients had evidence of elevated pulmonary artery pressure by echo

doppler and most of them had systolic pulmonary artery pressure in the range

between 30 to 50 mmHg.
 40

DISCUSSION

AGE DISTRIBUTION

I used the lower age of thirty years to calculate my estimate because this

was the most frequently available cut off age in the reported studies. Moreover

the disease is very rare below this age.

It is found that obstructive air way disease is more common in the middle

and old age. This is because

- The risk of COPD increases with increasing age because it is related to

smoking pack years and aging per se has a cumulative effect of exposure

to environmental stress.

- Mostly, the patients tend to ignore the initial symptoms and with

increasing age, the symptoms worsen and they report to the hospital

only at this juncture.

- With improving medical care, the life expectancy tends to increase and

with it the problem of COPD will also increase with advancing age.
 41

SEX DISTRIBUTION

In my study, the male is to female ratio is 2.12: 1

Sex distribution of COPD in adults (> 30 years of age) in different parts

of the country is generally similar.

The following is the male female ratio in the Indian studies:

Table 15: Male female ratio in Indian studies

Authors Year Population M:F

Wig et al 1964 Rural Delhi 1.32 : 1
Viswanathan 1966 Patna 1.59 : 1
Sikand et al 1966 Delhi 1.63 : 1
Bhattacharya et al 1975 Rural UP 1.49 : 1
Viswanathan & Singh 1977 Delhi – Rural 1.34 : 1
Urban 1.86 : 1
Thiruvengadam et al 1977 Madras 1.58 :1
Charan 1977 Rural Punjab 1.40 : 1
Radha et al 1977 New Delhi 1.76 : 1
Malik 1986 Chandigarh – Rural 1.92 : 1
Urban 2.31 : 1
Jinda 1993 Chandigarh 2.60 : 1
Ray et al 1995 Madras area 1.60 : 1

The prevalence was uniformly higher among male in all reported

studies. The male : female ratio vary from 1.32 : 1 to 2.60 : 1 with the median

ratio at 1.60 : 1.
 42

From the two south Indian studies which were carried out mainly in

Madras region at different times, (1977 and 1995) the male female ratio was

fairly constant maintaining at around 1.6: 1 which is that of the national

average.

The male female ratio tends to be much higher in case of urban

population. Of several possible reasons which might account for a higher

prevalence among males, the most important is the habit of smoking of

tobacco.

SMOKING PATTERN

The reported smoker: non-smoker prevalence ratio ranged from 61.6 to

91.1 % in ten different population studies. The median value was around

82.3%.

In my study, the ratio is about 66% of smokers, the majority of non –

smokers in my study were female population. The greater the pack years, the

greater the prevalence of COPD.

Tobacco was introduced in India by the Portugese 400 years ago. Since

then, tobacco consumption continued to rise in India. It has been estimated that

there are 1.1 billion smokers worldwide and 182 million (16.6 %) of them live

in India.

It has been predicted by WHO that more than 500 million people alive

today will be killed by tobacco by 2030. Tobacco is used for smoking as well
 43

as in smokeless forms in India. Among the tobacco smokers, beedi smokers

constitute 40%, cigarette smokers 20% and those using smokeless forms 40%.

The prevalence of tobacco use during 1993 to 1994 was 23.2% in male

(any age) and 4% in female in urban areas, 33.6 % in male and 8.8 % in female

in rural areas.

Smokers suffer an irreversible FEV1 loss of 4.4 to 10.4 ml per pack year

smoked. Cigarette smoking also retards the normal increase in expiratory flow

that occurs during growth in childhood or adolescence. The duration and

intensity are of equal importance in determining these effects.

Smoking cessation is associated with a small improvement in lung

function, decrease in coughing and sputum expectoration and normalization of

the rate of annual decline in lung function.

PULMONARY FUNCTION TEST

The primary problem in obstructive lung disease is an increased airway

resistance. For each measurement of pulmonary function there is a normal

value and range of normal limits. A common method of comparison is to

compute a percentage of predicted normal values according to the equation.

% predicted is equal to:

Measured value
x 100
Predicted normal value
 44

Predicted values

Predicted values vary as per age, sex, height and ethnic groups, are

obtained by large scale studies in the community and are readily available for

use. Values above 80 % of predicted are generally considered as normal. For

patients with deformity of the thoracic cage such as Kyphoscoliosis, the arm

span from finger tip to finger tip can be used as an estimate of height.

Caucasians have the largest FEV1 and FVC and of the various ethnic

groups, Polynesians are among the lowest. There is little difference in PEF

between ethnic groups. The values for black Africans are 10 to 15 % lower

than the Caucasians of similar age, sex and height because for a given standing

height, their thorax is shorter. The Chinese have been found to have an FVC

about 20 % lower and Indians about 10 % lower than matched Caucasians.

Approximate conversion factors for adjusting European reference values

of FVC and FEV1 for Indians are 0.9 for North Indians and 0.87 for south

Indians.

SPIROMETRY AND COPD

- Spirometry is needed to make a firm diagnosis of COPD.

- Together with the presence of symptoms, spirometry helps in staging

COPD severity and can be a guide to specific treatment steps.

- The lower the % predicted FEV1 the worse the subsequent

prognosis.
 45

- FEV1 declines over time and faster in COPD than in healthy

subjects.

- Spirometry can be used to monitor disease progression, buto to be

reliable, the intervals between the measurements must be atleast 12

months.

Staging

Once diagnosed, there are no widely accepted staging or severity scoring

systems for patients with COPD. At present, we grade the disease based on a

single objective physiologic measure such as FEV1.

FEV1 as a % of its predicted value is the best single correlate of

mortality in COPD. However, it is not until values fall to < 50% of predicted

that mortality begins to increase. It follows that there is a need for a more

comprehensive staging system that includes age, FEV1, ABG, body mass

index, time walked distance, possible bio markers and genetic markers.

CHEST X-RAY

The main utility of the chest x-ray lies in excluding or suggesting

alternate diagnoses that could cause a patient’s respiratory symptoms.

In patients with severe emphysema, the chest x-ray may reveal bilateral

lung hyperinflation with flattened diaphragms or the presence of bullae,

characterized by thin arcuate lines circumscribing areas of radiolucency .It is

important to bear in mind, how ever that a normal chest x-ray does not exclude

the presence of emphysema. In one study, spirometry and HRCT were

 46

performed on individuals with more than thirty pack years of smoking and

normal chest x-rays .It was found that 58% of these individuals had evidence of

significant emphysema.

In chronic bronchitis, the principle abnormalities are bronchial wall

thickening and an increase in lung markings which is sometimes termed “dirty

chest”, refers to a general accentuation of linear markings throughout the lungs

associated with loss of definition of vascular markings. Bronchial wall

thickening may be manifested as ring shadows end on or as tubular shadows en

face (tram tracks).

The chest x-ray may also reveal radiographic changes of pulmonary

hypertension in COPD .Patients can have right main pulmonary artery >16 mm

in diameter and left main pulmonary prominence below aortic knuckle with

pruning or poorly visualized peripheral vasculature .In lateral view right

ventricular encroachment into the retrosternal air space can be seen .

ARTERIAL BLOOD GAS ANALYSIS

In my study, hypoxemia was found in 22 patients and hypercapnia. The

hypercapnia was found only in patients having severe or very severe COPD.

Arterial blood gases are commonly abnormal; as a rule, the more the

severe the disease, the frequent the hypoxemia and hypercapnia. Arterial

hypoxemia is the result of alveolar hypoventilation and ventilation – perfusion

mismatching.
 47

In COPD of mild to moderate severity, hypoxemia exits without

hypercapnia. Although the V/Q inequality impairs both the uptake of oxygen

and elimination of carbon dioxide , the tendency for elevation of PaCO2 is

overcome by an increase in alveolar ventilation to well perfused units

.However ,the increase in ventilation cannot correct the hypoxemia because of

the nonlinear shape of the oxygen dissociation curve .

An increase in arterial PaCO2 does not generally occur until FEV1 is

less than approximately 1.2 litres, and the pressure of hypercapnia in a patient

with FEV1 > 1.5 litres should raise the possibility of central hypoventilation or

obstructive sleep apnea.

Patients with COPD may experience episodic arterial desaturation

during sleep, being more severe in patients categorized as blue bloaters than

pink puffers. The desaturation is more during the REM sleep, that is partly due

to the phasic inhibition of intercostal inspiratory muscle tone that is

characteristic of REM sleep.

Approximately 20% of patients with COPD and normal awake arterial

Oxygen tension have nocturnal, nonapneic oxygen desatuation. Exertional

oxygen desaturation is also common. These episodes are ameliorated with

supplemental oxygen.

Consequently, exercise and sleep oximetry should be completed in all

patients with pulmonary hypertension. A formal overnight polysomnogram is

indicated if the clinical presentation suggests sleep apnea.

 48

In a recent prospective study of 43 patients with pulmonary arterial

hypertension, with normal resting oxygenation, it was found that 70% had
evidence of nocturnal hypoxemia.

ELECTRO CARDIOGRAPHIC FINDINGS

The ECG signs satisfying the right ventricular hypertrophy (RVH)

criteria was found in 28 cases.

Diagnostic criteria for RVH for persons older than 30 years of age

-
Right axis deviation > + 110o

- Tall R wave in V1 > or = 7 mm, S wave in V1 < or = 2 mm

- R/S ratio in V1 > 1, R/S ratio in V5 or V6 or = 1

- S wave V5 or V6 > 2 mm

- qR pattern in V1 ( increases specificity)

- Most important is scrutiny for right atrial enlargement, peaked P

waves with an amplitude in V1, V2 or V3 > 1.5 mm or > 2.5 mm in
II, III, aVF.

- More than or equal to two criteria are required for the diagnosis of
RVH.

In an analysis of the contribution of individual signs in defining the long

term prognosis of COPD patients, it was found that P wave axis of more than
or equal to + 90o (a sign of severe right atrial over load ) and the SI, SII, SIII
pattern are independent negative prognostic predictors for survival. In the
 49

patients presenting with one or both of these signs, had a three year survival
rate of 44 and 14 % respectively versus 50 and 61% for patients having other or
no use ECG signs of chronic corpulmonale. The remaining signs of chronic
corpulmonale like RBBB, low voltage QRS, SIQ3 pattern were less
consistently associated with poor survival.

A P wave axis > or = 700 qualifies as the ECG hallmark of, and thus a

screening criterion for COPD. A P wave axis more than or equal to 900

probably identifies the stage of lung hyperinflation corresponding to very

severe or almost terminal illness. In the two studies assessing this sign, its

prevalence was known to be 24 % and 15% respectively.

Although highly specific, ECG is generally insensitive in detecting

pulmonary arterial hypertension (PAH). Kilcoyn et al evaluated the ECG of

200 patients with COPD and Corpulmonale and noted at least one of the

following changes:

A rightward shift of the mean QRS axis 30 degrees or more from its

previous position

- Inverted biphasic or flattened T waves in precordial leads

- ST depression in II, III, AVF

- Right bundle branch block (RBBB)

Incalzi et al reported that an SI, SII, SIII pattern, right atrial overload

and alveolar – arterial oxygen gradient more than 48 mmhg during oxygen

therapy were the strongest predictors of death.

 50

SI, SII, SIII pattern is a relatively uncommon finding not highly specific

for COPD. It reflects an abnormal wave front rightward and superiorly oriented

and opposed to the electrical forms of ventricular free wall. Low voltage QRS

is frequently associated with chronic corpulmonale from COPD, but not

associated with corpulmonale from other pulmonary diseases.

Kok – Jensen studied the ECG of 228 patients between 40 to 69 years of

age with COPD. According to him, the survival was very poor in the groups of

patients with an ECG showing a QRS axis + 900 to 1800 and a PII amplitude of

0.20 mv or more. Only 37% and 42% of the patients with these changes were

alive after four years. Patients with changes only in standard leads had a

significantly better survival than those with changes in precordial leads as well.

ECHOCARDIOGRAPHIC FINDINGS

In my study, 21 patients out of 28 who had evidence of right ventricular

hypertrophy had elevated pulmonary artery pressure by Doppler

echocardiography (> 30 mmhg systolic or > 20 mmhg mean pulmonary artery

pressure).

Echocardiographic screening for pulmonary hypertension is based on

identification of the tricuspid regurgitant jet (TR), absent in normal individuals.

Measurements of TR velocity (m / sec) provides an estimate of the back flow

between the right ventricle and the right atrium. The systolic pulmonary artery

pressure is estimated by the modified Bernoulli equation which is:

P = 4 V2
 51

where V is the velocity of the tricuspid regurgitant jet. By adding this pressure

gradient to an estimate of the right atrial pressure, the right ventricle peak

systolic pressure is determined. The right ventricle peak systolic pressure

approximates pulmonary artery systolic pressure (PSAP) obtained by right

heart catheterization.

Numerous studies have examined the correlation between right

ventricular systolic pressure (RVSP) as estimated by Doppler

echocardiography and RVSP as directly measured during right heart

catheterization, and most of the studies reported a relatively tight correlation

(the r value ranged from 0.57 – 0.95). In a study by Hinderliter and colleagues,

systolic pulmonary artery pressure was underestimated by atleast 20 mmhg in

31% of patients. Other studies have demonstrated that the concordance

between Doppler echocardiography and direct measurement via right heart

catheterization worsens as the pressure rises, with poorer correlation when the

systolic pulmonary arterial pressure is over 100mmhg.

P Sahoo and Misra et al observed that in their ECG and

echocardiographic evaluation of 50 cases, ECG abnormalities were found in 24

cases. Out of these, 20 cases had echocardiographic evidence of raised

pulmonary artery pressure.

In addition, 2 dimensional echocardiography can be used to assess RV

dimensions and wall thickness. Pulmonary artery hypertension can also be

assessed with pulsed Doppler echocardiography from the sub – xiphoid region

using a general purpose ultrasound device.

 52

CONCLUSION

In my study of 50 cases of COPD, the conclusions are the following:

- COPD is commonly seen in persons above 40 years of age ie., in the

middle and old aged people.

- It is more common among males.

- It is associated with the smoking pattern of more than 20 pack years. Its

severity increases with increasing age and duration of smoking.

- ECG abnormalities suggestive of pulmonary hypertension (Right

ventricular hypertrophy) was found in more than half of these cases.

Poor progression with R/S is < 1 was found in 12 cases, right ventricular

strain patterns like ST depression in II, III AVF and T wave inversion

was found in 7 and 6 cases respectively, low voltage QRS in 5 cases.

Other rare ECG abnormalities like lead I sign and SI, S II, S III was

found in 2 and 1 cases respectively. Rhythm abnormalities like

ventricular ectopics, RBBB are found in 2 cases and multi focal atrial

tachycardia in 1 case.

- The presence of raised pulmonary artery pressure was confirmed using

the Doppler Echo in 75 % of the patients showing ECG evidence of

right ventricular hypertrophy.

 53

SUMMARY

COPD is a major and increasing health problem which is predicted to

become the third commonest cause of death and fifth commonest cause of

disability in the world by the year 2020. Despite its enormous global

importance, there has been relatively little research into COPD and it is the

most under-funded disease in relation to the global burden of diseases.

This study was carried out to see the ECG and Echocardiographic signs

in COPD. It was conducted in 50 cases of COPD diagnosed clinically and

confirmed by Spirometry. It is an observational study and the relevant

information was obtained in a predesigned proforma using interview technique.

All the necessary investigations was done and ECG was done in all cases. 2 D

and Doppler Echocardiography was done in cases showing ECG evidence of

right ventricular hypertrophy (RVH). The results were carefully documented.

ECG evidence of RVH was found in 28 cases, out of which 21 cases was

confirmed using echocardiography. Thus, raised pulmonary artery pressure was

found in 75 % of cases showing ECG evidence of Right Ventricular

Hypertrophy.
 LIST OF ABBREVIATIONS

ABG Arterial Blood Gas

ATS American Thoracic Society
COPD Chronic Obstructive Pulmonary Disease
CXR Chest X-Ray
DALY Disability Adjusted Life Years
ECG Electro Cardio Gram
ELISA Enzyme Linked Immunosorbent Assay
FEV 1 Forced Expiratory Volume in one second
FVC Forced Vital Capacity
GOLD Global Initiative on Obstructive Lung Disease
HRCT High Resonance Computerized Tomogram
HIV Human Immunodeficiency Virus
IVS Inter Ventricular Septum
PAP Pulmonary Artery Pressure
PEFR Peak Expiratory Flow Rate
PFT Pulmonary Function Test
RA Right Atrium
RBBB Right Bundle Branch Block
RV Right Ventricle
TNF Tumor Necrosis Factor
WHO World Health Organization
 BIBLIOGRAPHY

1. Eduardo bossone, Bruno dino ,Alprodo mazzaet et al , Pulmonary arterial

hypertension – The key role of echocardiography : chest ,2005 :127:1836-
1843.

2. Miller M.R.,Crapo R.,Hankinson J.,et al.General considerations for lung

function testing. Eur Respir J 2005;26:153-161

3. Barbera JA , Perinado VI ,Santos , pulmonary hypertension in chronic

obstructive pulmonary disease , Eur Respir J ,2003:21:892-905.

4. Areasoy SM , Christie JD , Ferrari VA ,et al , Echocardiographic

assessment of pulmonary hypertension in patients with advanced lung
disease , Am J Respir Crit care Med 2003;167:735-740.

5. Weitzenblum E , Chronic corpulmonale , BMJ Heart 2003; 89: 225-230.

6. Croxton TL , Weinmann GG ,et al,Future research directions in chronic

obstructive pulmonary disease , Am J Respir Crit care Med 2002;105:838-
844.

7. Sashidar .K,Gupta .D , et al ,Emphysema in heavy smokers with normal

chest radiography: Detection and quantification by HRCT , Acta Radiol
2002;43:60-65.

8. Taylor DH Jr , Hassel blad V , Henley SJ , et al , Benefits of smoking

cessation for longevity, Am J public health 2002,92:990-996.

9. SK. Jindal, A.N Aggarwal and D.Gupta , A review of population studies

from India to estimate National Burden of COPD and its association with
smoking ,Indian J Chest Dis Allied Sei , 2001;43:147-149.

10. Incalzi,Fuso,et al , The prognostic role of electrocardiography in chronic

obstructive pulmonary disease ;Ital Heart J 2001;2:78-80.
11. Pauwels RA , Buist AS, Calverley PMA , et al ,Global strategy for the
diagnosis,management and prevention of chronic obstructive pulmonary
disease ;NHLBI/WHO Global initiative for chronic obstructive lung
disease(GOLD) workshop summary, Am ,J Respir Crit care ;March
2001,163:1256-1276.

12. Chapman KR,Tashkin DP,Pye DJ,Gender Bias In Diagnosis of

COPD,CHEST 2001;119:1691-1695

13. Wright JL.Levy RD,Churg A,Pulmonary hypertension in Chronic

Obstructive Pulmonary Disease;Current theories of pathogenesis and their
implications for treatment,Thorax 2000;60:605-609

14. Bossone E.,Avolar E,Bachs DS, et al,Diagnostic value of resting tricuspid

regurgitant velocity and right ventricular ejection flow parameters for
detection of exercise induced pulmonary arterial hypertension,Int J Cardio
Vasc Imaging,2000;6:429-436

15. Incalzi RA,Fuzo L,DeRosa M.et al,Electrocardiographic signs in chronic

cor pulmonale;A negative prognostic finding in COPD,Circulation
1999;99(12);1600-1605

16. Tramarin R,Marchandise B, et al,Doppler echocardiographic Evaluation of

Pulmonary artery pressure in chronic obstructive pulmonary disease,Eur
Heart J 1999;12:103-111

17. Baljepally R et al, Electrocardiographic screening for emphysema:the

frontal plane P wave axis, Clin Cardio, 1999;22:226-228

18. Senior RM,Shapiro SD,Chronic Obstructive Pulmonary

Disease:Epidemiology,Pathophysiology and Pathogenesis in Fishman’s
Pulmonary Diseases and Disorders,third ed, AD Fishman’s et al, 1998,659-
681

19. Teic, Hodge DO,et al, Doppler echocardiographic index for assessment of
global
20. right ventricular function, J Am Echocardiogr, 1996;9:838-847

21. Ray D,Abel R,Selvaraj KG,A 5 year prospective epidemiological study of

chronic obstructive pulmonary disease in rural south India,Indian J Med
Res 1995;101:238-244

22. Pande JN,Khilnani GC,Epidemiology and etiology in COPD and its

association with smoking,Mumbai;Indian college of Physicians;1997:10-22

23. The Global Burden of Disease:a comprehensive assessment of mortality

and disability from disease, injuries and risk factors and 1990 and projected
to 2020,Cambridge Harvard University Press,1996

24. Oswald-Mammosen M,Weitzenblum et al,Prognostic factors in COPD

patients receiving long term oxygen therapy;Importance of pulmonary
artery pressure,Chest107:1193-1198,1995

25. Harrison’s Principle of Internal Medicine,16 th edition,Vol 2;1547-1554

26. Leo Schamroth-An introduction to electrocardiography, 7 th ed:233-240

27. Anthonisen NR,Connett JE,Kiley JP, et al;Effects of smoking intervention

and the use of an inhaled anticholinergic bronchodilator on the rate of
decline of FEV1:The lung health study,JAMA,2721497-1505,1994

28. American Thoracic Society(ATS) Statement on standardization of

spirometry-1994 update,Am J Crit Care Med 1995,152:1107-1136

29. Crapo R.O. Pulmonary function testing,New Eng J Med 1994;331:25-30

30. Weitzenblum E , Apprill M , Oswald M , et al , Pulmonary hemodynamics

in patients with chronic obstructive pulmonary disease before and during an
episode of peripheral edema, Chest 1994;105:1377-1382.

31. Macnee W,Pathophysiology of cor pulmonale in chronic obstructive

pulmonary disease, Am J Respir Crit Care Med 1994;150:833-852
32. Singh VK and Jain SK,Effect of airflow limitation on ECG in COPD ,
Indian JL Chest Diseases Allied Sci,Jan-Mar 1991 BI CD;Medlers-B.R.S

33. Incalzi R, Fuso et al,Cardiac arrhythmias and left ventricular function in

respiratory failure from COPD, Chest 1990;97:1092-97

34. Berger M,Haimowitz A,Van Tosh A,et al,Quantitative assessment of

pulmonary hypertension in patients with tricuspid regurgitation using
continuous wave Doppler ultrasound, J Am Coll Cardiol 1985;12:359-365

35. Ikeda K,Kukota I,Takashi k, P wave changes in obstructive and restrictive

lung diseases,J Electrocardiol,1985;18:233-238

36. Cosio M,Ghezzo H,Hogg J.C.,et al. The relationship between structural
changes in small airways and pulmonary function tests. N Engl J Med
1978;298:1277-1281

37. Kok Jensen A,Simple ECG features of prognostic importance in severe

COPD,Scand J Respir Dis 1975;56:273-284

38. Schmasc CC,Maisel JC et al,The electrocardiogram in emphysema with and

without chronic airway obstruction,1971;chest 60:328-334

39. Silver HM,Calatayud JB, Evaluation of QRS criteria in patients with

COPD,1971,Chest;59;153-159

40. Kamper D,Bloomfield S et al,The variability of electrocardiographic criteria

of chronic obstructive pulmonary disease,1970;Am Heart J,80:445-452

41. Burch GE,DePasquale N.P,The electrocardiographic diagnosis of

pulmonary heart disease,1963,Am J Cardiol;11:622-638
 LIST OF FIGURES

Fig 1 Spirometer

Fig 2 Patient performing spirometry

Fig 3 Spirometry report

Fig 4 Chest x-ray showing emphysema

Fig 5 Chest x-ray -chronic bronchitis showing prominent broncho

vascular markings

Fig 6 Chest x-ray showing pulmonary arterial enlargement

Fig 7 ECG showing low voltage QRS

Fig 8 ECG showing lead I sign

Fig 9 ECG showing p pulmonale

Fig 10 ECG showing RVH

Fig 11 ECG showing RBBB

Fig 12 ECG showing multifocal atrial tachycardia

Fig 13 Doppler echo showing regurgitant jet with dilated RA and RV

 LIST OF TABLES

Table 1 Clinical hallmarks of COPD

Table 2 Echo and Color Doppler features of patients with PAH

Table 3 Risk factors for COPD

Table 4 Severity of COPD

Table 5 Age – distribution

Table 6 Sex distribution

Table 7 Smoking pattern

Table 8 Spirometry showing FEV1/FVC %

Table 9 Spirometry showing post bronchodilator FEV1 %

Table 10 Chest x-ray findings

Table 11 Measurement of PaO2

Table 12 Measurement of PCO2

Table 13 Electro cardiographic findings

Table 14 Measurement of pulmonary artery pressure by echo-doppler

Table 15 Male female ratio in the Indian studies

 MASTER CHART
AGE / FEV1/ QRS P R/S IN R/S IN RV PAP
S NO. NAME FVC FEV1 RBBB OTHERS
SEX FVC % AXIS PULM V1 V6 STRAIN (mmhg)

1 Adam mohammed 48 / M 1.8 0.7 44 +90 <1 <1 36

2 Noor jehan 48/ F 2.1 1.2 57 +80 <1 >1

3 Daisy Solomon 50/F 1.8 1.0 55 +70 <1 =1
Sinus
4 Krishnaiah 35 / M 2.0 1.3 68 +70 <1 >1
tachycardia
Low volatage
5 Malarkodi 50/F 1.7 0.8 77 +110 =1 <1 34
QRS
6 Dhanalakshmi 52/F 1.9 0.9 47 +120 + >1 >1 + 38 SI, SII, SIII
7 Chakravarthi 45/M 2.1 1.2 27 +80 <1 >1
8 Sundar 43/M 1.8 1.0 56 +70 <1 >1
9 Gopalakrishnan 58/M 1.9 1.0 53 +110 =1 >1 36
10 Govindan 50/M 2.4 1.1 48 +90 <1 <1
11 Jayanthy 56/F 2.1 1.2 57 +70 <1 >1 + 40
12 Mariamma 40/F 1.8 0.9 50 +80 <1 >1
13 Shankar 37/M 2.3 1.9 61 +90 <1 >1 + Lead 1 sign
Ventricular
14 navaneethan 57/M 2.2 1.1 50 +70 <1 >1
ectopics
15 Kandaswamy 64/M 2.1 1.0 47 +90 <1 <1 38
16 Sankarnarayan 57/M 2.1 1.2 57 -60 <1 >1
17 Kannammal 75/F 1.4 0.5 36 +140 + >1 <1 + 64 Low voltage
 AGE / FEV1/ QRS P R/S IN R/S IN RV PAP
S NO. NAME FVC FEV1 RBBB OTHERS
SEX FVC % AXIS PULM V1 V6 STRAIN (mmhg)
QRS
Sinus
18 Kuppammal 40/F 3.1 2.1 67 +70 <1 >1
tachycardia
19 Agis Khan 45/M 1.4 0.8 57 +80 <1 >1
20 Unnamalai 62/F 1.8 0.7 44 +120 + >1 >1 72
21 Vasantharaj 42/M 2.3 1.3 56 +80 <1 >1
22 Jothi 56/M 1.8 1.0 55 +70 <1 >1
Low voltage
23 Chandran 53/M 2.1 1.2 57 +80 <1 >1
QRS
24 Ethiraj 53/M 2.0 1.0 50 +70 <1 >1
25 Rosamma 55/F 1.8 0.9 50 +90 <1 >1 40
26 Mahalingam 59/M 1.8 1.0 56 +70 <1 >1 + 42
27 Kannammal 50/F 1.8 1.0 55 +80 <1 <1
28 Ramadas 60/M 2.2 1.0 49 +90 <1 >1 Lead 1 sign
Ventricular
29 Arumugam 40/M 1.7 1.0 59 +90 <1 >1
ectopics
30 Perumal 55/M 1.8 0.9 50 +70 <1 =1 42
31 Jayaraman 59/M 2.1 0.9 46 +90 <1 >1
32 Pachaiammal 40/F 1.8 0.9 50 +90 <1 >1
33 Raja 42/M 1.7 0.7 41 +120 + >1 <1 48
34 Radhakrishnan 56/M 1.8 1.0 56 +70 <1 >1
35 Ponnusamy 52/M 1.9 0.8 50 +80 <1 =1
 AGE / FEV1/ QRS P R/S IN R/S IN RV PAP
S NO. NAME FVC FEV1 RBBB OTHERS
SEX FVC % AXIS PULM V1 V6 STRAIN (mmhg)
36 Lalitha 45/F 2.4 1.1 48 +110 + =1 <1 48
Multifocal
37 Ranjitham 55/F 1.9 1.0 52 +70 <1 >1 atrial
Tachycardia
38 Padmavathy 56/F 1.6 0.7 45 +110 =1 >1 46
39 Kanikannan 82/M 1.6 0.6 37 +110 <1 <1 50
Sinus
40 Selvaraj 68/M 1.7 0.7 38 +120 + >1 >1 + 44
tachycardia
41 Manickam 60/M 1.8 1.0 55 +90 <1 >1
42 Sethuraman 75/M 1.7 0.7 41 +120 >1 >1 + 54
43 Manoharan 60/M 1.9 1.0 52 +90 <1 <1
44 Subramani 60/M 1.8 1.0 55 -30 <1 =1
Low voltage
45 Venkatesan 60/M 1.8 0.9 50 +70 <1 >1
QRS
46 Stalin Rehman 62/M 1.5 0.6 40 +110 + =1 >1 56
Low voltage
47 Satyanarayanan 64/M 1.8 0.7 44 +100 <1 <1 34
QRS
48 Abdul khuda 61/M 1.9 0.9 48 +100 <1 <1 56
49 Kanakamma 55/F 1.7 0.7 41 +120 + >1 >1 + 38
50 Ashok 58/M 1.8 0.9 50 +80 <1 >1
 Fig 1. SPIROMETER

Fig 2. PATIENT PERFORMING SPIROMETRY

 AGE- SEX DISTRIBUTION
30

25

20
% OF PATIENTS

15

Male

Female
10

0
30-39 40-49 50-59 60 & above
AGE in years
Fig 3. SPIROMETRY REPORT
Fig 4.EMPHYSEMA
Fig 5.CHRONIC BRONCHITIS SHOWING PROMINENT BRONCHO

VASCULAR MARKINGS
Fig 6.CHEST X-RAY SHOWING PULMONARY ARTERIAL

ENLARGEMENT
Fig 7.ECG SHOWING LOW VOLTAGE QRS
Fig 8. ECG SHOWING LEAD I SIGN
Fig 9.ECG SHOWING P PULMONALE
Fig 10. ECG SHOWING RVH
 Fig 11.ECG SHOWING RBBB

Fig 12.ECG SHOWING MULTIFOCAL ATRIAL TACHYCARDIA

Fig 13. DOPPLER ECHO SHOWING REGURGITANT JET WITH

DILATED RA AND RV